A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Non-Alcoholic Fatty Liver Disease (NAFLD)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

October 18, 2025

Study Completion Date

October 18, 2025

Conditions

Healthy VolunteersNon-alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

ALN-PNP - Part A

Administered by subcutaneous (SC) single ascending dose (SAD)

DRUG

ALN-PNP - Part B

Administered by SC parallel single dose

DRUG

Placebo (PB)

Administered by SC injection

Trial Locations (6)

Genoma Research Group ,Inc, Miami

Med Research of Florida,LLC, Miami

Tandem Clinical Research, Marrero

Pioneer Research Solutions, Houston

Velocity Clinical research, Los Angeles

California Clinical Trials Medical Group, Glendale

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY